Latest news

• Sanofi trumpets new IGlarLixi data after regulatory delay

  Sanofi is highlighting new data for its IGlarLixi combination drug for diabetes showing it is more effective at controlling mealtime blood glucose than its Lantus blockbuster. ... The FDA scuppered those plans last month by announcing a delay of up to

• Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

  The FDA has asked for more information on Sanofi and Zealand Pharma's IGlarLixi combination drug for diabetes, giving a rival drug from Novo Nordisk a chance to be first to ... The FDA is due to deliver a verdict on Xultophy next month, with a decision

• Sanofi boosted by iGlarLixi trials at ADA

  Sanofi's combination insulin/GLP-1 agonist drug iGlarLixi (formerly LixiLan) has met objectives in two phase III trials, setting up a showdown in the diabetes market. ... The positive data comes as iGlarLixi approaches an FDA decision on approval - due

• FDA panel backs Sanofi's insulin/GLP-1 agonist combo

  The FDA panel voted 12 to 2 in favour of approval for iGlarLixi - a combination of insulin glargine and GLP-1 agonist lixisenatide - as an adjunct to diet and exercise to ... iGlarLixi and other new drugs such as longer-acting Lantus follow-up Toujeo are

• FDA advisors back Novo Nordisk's IDeglira combination

  The committee's decision could also give Novo a boost over its diabetes rival Sanofi, whose similar combination of iGlarLixi (which brings together Lantus and Lyxumia) is due to be reviewed